<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704496</url>
  </required_header>
  <id_info>
    <org_study_id>25325</org_study_id>
    <nct_id>NCT00704496</nct_id>
  </id_info>
  <brief_title>The Effect of Pseudoephedrine on Rhinitis and Sleep</brief_title>
  <official_title>The Effect of Pseudoephedrine on Rhinitis and Sleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that pseudoephedrine, a sympathomimetic amine commonly used as a
      decongestant, will decrease nasal congestion leading to increased patency of the nose and a
      decrease in nighttime sleep fragmentation in individuals with year round perennial allergic
      rhinitis (PAR). This decrease in sleep fragmentation will reduce daytime somnolence and
      fatigue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis is that pseudoephedrine, a sympathomimetic amine commonly used as a
      decongestant, will decrease nasal congestion leading to increased patency of the nose and a
      decrease in nighttime sleep fragmentation in individuals with year round perennial allergic
      rhinitis (PAR). This decrease in sleep fragmentation will reduce daytime somnolence and
      fatigue. We studied patients treated with placebo compared to FDA approved dose of
      pseudoephedrine and assessed sleep, QOL and daytime sleepiness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Sleep Associated With the Use of Pseudoephedrine as Compared to the Placebo</measure>
    <time_frame>3 years</time_frame>
    <description>sleep improvement by subjective questionnaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Daytime Somnolence With Pseudoephedrine as Compared to Placebo</measure>
    <time_frame>3 years</time_frame>
    <description>daytime sleepiness by subjective questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Rhinitis</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudoephedrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pseudoephedrine is a 240 mg PO per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine</intervention_name>
    <description>Pseudoephedrine is a 240 mg PO per day</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pseudoephedrine</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 65.

          2. History of allergic rhinitis.

          3. The ability to be placed on placebo without significant compromise in the quality of
             life.

          4. General good health.

          5. Ability to comply with the protocol and sign an informed consent.

          6. Have daytime sleepiness by history.

          7. Have poor sleep by history.

          8. Have fatigue by history.

          9. Have a skin test or RAST test to a perennial allergen (indoor mold, dog, cat, mite)
             with correlating symptoms.

        Exclusion Criteria:

          1. Age fewer than 18 or over 65 years.

          2. A history of sleep apnea.

          3. Atopic diseases other than allergic rhinitis, such as atopic dermatitis or asthma.

          4. Non-allergic rhinitis.

          5. Hypertension

          6. Diabetes Mellitus

          7. Inability to tolerate pseudoephedrine

          8. Significant other diseases as determined by the investigator.

          9. Use of a research medication within 30 days.

         10. Use of a nasal steroid or topical antihistamine or decongestant within 30 days.

         11. Use of beta-blockers, antidepressants, oral decongestants, oral steroids, or
             H2-blockers.

         12. Excessive use of alcohol or drug abuse.

         13. Inability to stop medication use during run-in period.

         14. Use of an oral antihistamine within 1 week of enrollment.

         15. Failed to have benefit when pseudoephedrine was used for rhinitis or asthma in the
             past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J Craig, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2008</study_first_posted>
  <results_first_submitted>September 20, 2017</results_first_submitted>
  <results_first_submitted_qc>September 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2017</results_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Timothy Craig</investigator_full_name>
    <investigator_title>Timothy Craig, D.O.</investigator_title>
  </responsible_party>
  <keyword>Sleep, Pseudoephedrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>data disposed of and no longer in existence</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pseudoephedrine</title>
          <description>Pseudoephedrine is a 240 mg PO per day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>data disposed of and no longer in existence</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo
Pseudoephedrine: Pseudoephedrine is a 240 mg PO per day</description>
        </group>
        <group group_id="B2">
          <title>Pseudoephedrine</title>
          <description>Pseudoephedrine is a 240 mg PO per day
Pseudoephedrine: Pseudoephedrine is a 240 mg PO per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement of Sleep Associated With the Use of Pseudoephedrine as Compared to the Placebo</title>
        <description>sleep improvement by subjective questionnaires</description>
        <time_frame>3 years</time_frame>
        <population>data disposed of and no longer in existence</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Pseudoephedrine: Pseudoephedrine is a 240 mg PO per day</description>
          </group>
          <group group_id="O2">
            <title>Pseudoephedrine</title>
            <description>Pseudoephedrine is a 240 mg PO per day
Pseudoephedrine: Pseudoephedrine is a 240 mg PO per day</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Sleep Associated With the Use of Pseudoephedrine as Compared to the Placebo</title>
          <description>sleep improvement by subjective questionnaires</description>
          <population>data disposed of and no longer in existence</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Daytime Somnolence With Pseudoephedrine as Compared to Placebo</title>
        <description>daytime sleepiness by subjective questionnaires</description>
        <time_frame>3 years</time_frame>
        <population>data disposed of and no longer in existence</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Pseudoephedrine: Pseudoephedrine is a 240 mg PO per day</description>
          </group>
          <group group_id="O2">
            <title>Pseudoephedrine</title>
            <description>Pseudoephedrine is a 240 mg PO per day
Pseudoephedrine: Pseudoephedrine is a 240 mg PO per day</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Daytime Somnolence With Pseudoephedrine as Compared to Placebo</title>
          <description>daytime sleepiness by subjective questionnaires</description>
          <population>data disposed of and no longer in existence</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo
Pseudoephedrine: Pseudoephedrine is a 240 mg PO per day</description>
        </group>
        <group group_id="E2">
          <title>Pseudoephedrine</title>
          <description>Pseudoephedrine is a 240 mg PO per day
Pseudoephedrine: Pseudoephedrine is a 240 mg PO per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>data disposed of and no longer in existence</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>timothy craig,</name_or_title>
      <organization>milton s hershey medical center</organization>
      <phone>717-531-6525 ext 1</phone>
      <email>tcraig@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

